{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:14:47Z","timestamp":1788333287044,"version":"build-2803163510"},"reference-count":25,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Advanced therapy medicinal products are a rapidly expanding drug class based on genes, cells, and tissues, transforming the treatment of diseases, including haematologic cancers and genetic disorders, such as sickle cell disease and haemophilia. This review highlights that successful clinical implementation requires coordinated national strategies, regulatory support, sustainable funding, robust clinical and production infrastructure, and trained specialised personnel to ensure timely, safe, and equitable patient access.<\/jats:p>","DOI":"10.61409\/v12251027","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:57:50Z","timestamp":1788159470000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Advanced therapy medicinal products"],"prefix":"10.61409","author":[{"given":"Rasmus Roost","family":"Aabling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Louise Schacht","family":"Revenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Frangoul H, Locatelli F, Sharma A et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390(18):1649-1662 https:\/\/doi.org\/10.1056\/NEJMoa2309676","DOI":"10.1056\/NEJMoa2309676"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Pipe SW, Leebeek FWG, Recht M et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706-718. https:\/\/doi.org\/10.1056\/NEJMoa2211644","DOI":"10.1056\/NEJMoa2211644"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Musunuru K, Grandinette SA, Wang X et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025;392(22):2235-2243. https:\/\/doi.org\/10.1056\/NEJMoa2504747","DOI":"10.1056\/NEJMoa2504747"},{"key":"ref3","unstructured":"L\u00e6gemiddelstyrelsen. Regulering af innovative l\u00e6gemidler herunder avanceret terapi (ATMP), 2025. https:\/\/laegemiddelstyrelsen.dk\/da\/special\/regulering-af-innovative-laegemidler-herunder-avanceret-terapi-atmp-\/ (22. april 2026)"},{"key":"ref4","unstructured":"European Medicines Agency. CAT quarterly highlights and approved ATMPs, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/committee-report\/cat-quarterly-highlights-approved-atmps-december-2025_en.pdf (26. feb 2026)"},{"key":"ref5","unstructured":"U.S. Food and Drug Administration. Approved cellular and gene therapy products, 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products (25. nov 2025)"},{"key":"ref6","unstructured":"European Medicines Agency. Yescarta (axicabtagene ciloleucel), 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta (26. feb 2026)"},{"key":"ref7","unstructured":"European Medicines Agency. Luxturna (voretigene neparvovec), 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/luxturna (26. feb 2026)"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Keam SJ. Tabelecleucel: first approval. Mol Diagn Ther. 2023;27(3):425-431. https:\/\/doi.org\/10.1007\/s40291-023-00648-z","DOI":"10.1007\/s40291-023-00648-z"},{"key":"ref9","unstructured":"European Medicines Agency. Holoclar ex vivo expanded autologous human corneal epithelial cells containing stem cells, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/holoclar (8. jul 2025)"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ramzy A, Thompson DM, Ward-Hartstonge KA et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell. 2021;28(12):2047-2061.e5. https:\/\/doi.org\/10.1016\/j.stem.2021.10.003","DOI":"10.1016\/j.stem.2021.10.003"},{"key":"ref11","unstructured":"European Medicines Agency. Legal framework: advanced therapies, 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview\/legal-framework-advanced-therapies (9. dec 2025)"},{"key":"ref12","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation): Holoclar, 2014. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-holoclar_en.pdf (26. feb 2026)"},{"key":"ref13","unstructured":"European Medicines Agency. Assessment report: Holoclar, 2014. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/holoclar-epar-public-assessment-report_en.pdf (26. feb 2026)"},{"key":"ref14","unstructured":"European Commission. EudraLex: The rules governing medicinal products in the European Union. Volume 4: Good manufacturing practice, 2017. https:\/\/health.ec.europa.eu\/document\/download\/ad33d9dd-03f0-4bef-af53-21308ce2187d_en?filename=2017_11_22_guidelines_gmp_for_atmps.pdf (26. feb 2026)"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Juan M, Delgado J, Calvo G et al. Is hospital exemption an alternative or a bridge to European Medicines Agency for developing academic chimeric antigen receptor T-cell in Europe? Our experience with ARI-0001. Hum Gene Ther. 2021;32(19-20):1004-1007. https:\/\/doi.org\/10.1089\/hum.2021.168","DOI":"10.1089\/hum.2021.168"},{"key":"ref16","unstructured":"Medicinr\u00e5det. Overblik over ATMP-l\u00e6gemidler i Skandinavien, 2024. https:\/\/medicinraadet.dk\/nyheder\/2024\/overblik-over-atmp-laegemidler-i-skandinavien (11. dec 2025)"},{"key":"ref17","unstructured":"Medicinr\u00e5det. Stigende priser og spinkle data: derfor \u00f8nsker Medicinr\u00e5det mere risikodeling, 2024. https:\/\/medicinraadet.dk\/nyheder\/2024\/stigende-priser-og-spinkle-data-derfor-onsker-medicinradet-mere-risikodeling (26. feb 2026)"},{"key":"ref18","unstructured":"Medicinr\u00e5det. Nye pristilbud p\u00e5 ATMP-l\u00e6gemidler kan f\u00f8re til nye anbefalinger fra Medicinr\u00e5det, 2024. https:\/\/medicinraadet.dk\/nyheder\/2024\/nye-pristilbud-pa-atmp-laegemidler-kan-fore-til-nye-anbefalinger-fra-medicinradet (17. maj 2024)"},{"key":"ref19","unstructured":"Amgros. Alternative aftalemodeller, 2022. https:\/\/amgros.dk\/media\/3598\/oversigt-over-alternative-aftalemodeller-amgros-2022.pdf (26. feb 2026)"},{"key":"ref20","unstructured":"Dansk H\u00e6matologisk Selskab, Dansk Selskab for Klinisk Immunologi. Nationale retningslinjer for CAR-T behandling hos voksne, 2025. https:\/\/hematology.dk\/wp-content\/uploads\/2025\/02\/Nationale-retningslinjer-for-CAR-T-behandling-hos-voksne-Final-Version-03-02-2025.pdf (26. feb 2026)"},{"key":"ref21","unstructured":"European Medicines Agency. Summary of product characteristics: Carvykti, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf (10. dec 2025)"},{"key":"ref22","unstructured":"European Medicines Agency. Summary of product characteristics: Yescarta, 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yescarta-epar-product-information_en.pdf (10. dec 2025)"},{"key":"ref23","unstructured":"European Medicines Agency. Summary of product characteristics: Breyanzi, 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/breyanzi-epar-product-information_en.pdf (10. dec 2025)"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Palani HK, Arunachalam AK, Kulkarni U et al. Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial. Mol Ther Oncol. 2025;33(2):200977. https:\/\/doi.org\/10.1016\/j.omton.2025.200977","DOI":"10.1016\/j.omton.2025.200977"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:39:34Z","timestamp":1788331174000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V12251027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":25,"URL":"https:\/\/doi.org\/10.61409\/v12251027","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}